Breaking News Hits Wire: TC BioPharm (NASDAQ: TCBP) Makes Approx 189% Early Move

*Sponsored After an Approximate 1,041% Move in Under 3 Months From a Recent BioPharma Profile, Our Next Potential Breakout Idea is  TC BioPharm (NASDAQ: TCBP) TC BioPharm (NASDAQ: TCBP) is #1 On This Morning’s Watchlist. And Here’s Why… Low Float: With fewer than 585K shares in its float, TC BioPharm (NASDAQ: TCBP)’s limited supply could lead to the potential for significant swings.  $3 Analyst Target: HC Wainwright & Co. recently set a $3 target, highlighting strong upside potential from current levels. Oversold RSI Hints at Reversal: RSI levels (9-Day: 25.80%, 14-Day: 25.85%, 20-Day: 29.04%) show oversold conditions that could precede a potential trend reversal.  Leading Innovation in T-Cell Therapies: TC BioPharm (NASDAQ: TCBP)’s flagship therapy, TCB008, is advancing Phase II trials for AML, a difficult-to-treat cancer. AI-Driven Screening for Efficiency: A partnership with Carnegie Mellon University integrates AI to enhance donor screening and  therapy scalability. ACHIEVE Trial Shows Strong Progress: Positive safety data, dose increases, and plans for six clinical trial sites reflect steady momentum. Broad Pipeline Beyond Oncology: TC BioPharm (NASDAQ: TCBP) is developing therapies for antifungal infections and viral diseases to tackle urgent health needs. Consider Adding TC BioPharm (NASDAQ: TCBP) to  Your Radar This Week… December 18, 2024 Dear Reader, We just saw this news hit the wire as (TCBP) makes an approximate 189% early move. TC BioPharm (NASDAQ: TCBP) Announces Special Dividend On Wednesday, TC BioPharm (NASDAQ: TCBP) announced that its Board of Directors has approved a special dividend of 0.25 American Depositary Shares (ADSs) for every 1 ADS held, pending shareholder approval.  On the heels of this announcement, TC BioPharm (NASDAQ: TCBP) reached $1.36 in the pre-market, marking an approximate 189% move from yesterday’s close of $0.469. The company plans to hold a general meeting of shareholders on December 30, 2024, to finalize the dividend decision. If approved, the dividend will be declared the same day and will be payable to shareholders of record as of the close of trading on January 2, 2025. CEO Bryan Kobel stated, “We are extremely pleased to announce this special dividend. Our shareholders have been supportive of the company through a difficult capital markets environment, including the Company being the target of a nefarious and false short and distort campaign.” TC BioPharm is a clinical-stage biopharmaceutical company specializing in gamma-delta T-cell therapies for cancer treatment, particularly acute myeloid leukemia (AML). The company’s proprietary CryoTC technology supports its pivotal Phase 2b/3 clinical trial for AML by delivering frozen allogeneic gamma-delta T-cell products to clinics worldwide. The announcement of the special dividend marks a key milestone for TC BioPharm (NASDAQ: TCBP) as it continues advancing its innovative therapies while demonstrating a commitment to creating value for shareholders.  The market is now focused on the December 30 meeting, where the dividend decision will be finalized.  See full story here. Keep reading to see why TC BioPharm (NASDAQ: TCBP) is #1 on our watchlist this morning.  Less than two weeks ago, on December 6th, Benzinga reported that one of the country's oldest and most trusted institutions, HC Wainwright & Co., issued a $3 target on TC BioPharm (NASDAQ: TCBP). This suggests a potential upside of over 435% from today’s opening of approximately $0.56. After trending down to $0.45 today, TC BioPharm (NASDAQ: TCBP)’s shares now appear “Severely Oversold” and are worth considering for a potential reversal. To assess whether a company is oversold, Wall Street often turns to the Relative Strength Index (RSI) — a widely trusted momentum indicator. The RSI measures the speed and magnitude of price movements to identify overbought and oversold conditions, as well as potential reversal points.  It is plotted on a scale of 0 to 100, with readings below 30 signaling oversold conditions and readings above 70 indicating overbought territory. When RSI falls below 30, the company has entered oversold territory, which can signal a potential reversal. Here are TC BioPharm (NASDAQ: TCBP)’s current RSI levels: 9-Day: 25.80% 14-Day: 25.85% 20-Day: 29.04% What makes this even more compelling is that TC BioPharm (NASDAQ: TCBP) has a float of less than 585K shares, according to MarketWatch.  Companies with small floats like this are often highly volatile, and if demand increases, this scarcity of available shares can lead to the potential for significant swings.  From oversold technicals to explosive upside potential, TC BioPharm (NASDAQ: TCBP) has everything we look for in a company with breakout potential. Read on to see why it’s earned the #1 spot on our radar. TC BioPharm (NASDAQ: TCBP): The Global Leader in  Gamma-Delta T-Cell Therapy When it comes to revolutionizing the treatment landscape for acute myeloid leukemia (AML) and beyond, TC BioPharm (NASDAQ: TCBP) is boldly setting the pace.  This clinical-stage biopharmaceutical powerhouse is leveraging its unmatched expertise in gamma-delta T-cell therapy to deliver cutting-edge treatments for some of the most challenging cancers.  With its innovative pipeline, strategic collaborations, and relentless drive for progress, TC BioPharm (NASDAQ: TCBP) is not just a player in the immunotherapy game—it’s the leader. Gamma-Delta T-Cells: The Next Frontier At the heart of TC BioPharm (NASDAQ: TCBP)’s work lies a simple yet transformative idea: harness the innate power of gamma-delta T-cells.  These naturally occurring immune cells are a double-edged sword, embodying the qualities of both the innate and adaptive immune systems.  They’re highly selective, attacking diseased tissues while sparing healthy ones—a characteristic that sets them apart in the world of immunotherapy. The company’s flagship therapeutic, TCB008, is the first gamma-delta T-cell therapy to progress to Phase II/pivotal clinical trials in oncology.  This program is tackling refractory and relapsed AML, a condition notoriously difficult to treat. In preclinical studies, TCB008 has shown impressive cytotoxicity against AML cell lines while maintaining a robust safety profile.  In short, TC BioPharm (NASDAQ: TCBP) isn’t just offering hope; it’s delivering results. A Pipeline Packed with Potential TC BioPharm (NASDAQ: TCBP)’s pipeline is as diverse as it is promising. From next-generation gamma-delta T-cell therapies to CAR-T and CAR-NK platforms, this company’s development strategy is a masterclass in innovation. TCB008: Currently in the Phase 2b ACHIEVE trial, TCB008 is already changing the game for AML treatment. Preliminary data from early cohorts reveal significant cytotoxic effects with zero drug-related adverse events. TCBP’s dosing regimen of four doses over two weeks is a patient-centric approach, combining safety and efficacy to maximize impact. CAR-NK Therapies: TCBP’s CAR-NK assets are showing functional persistence and tumor regression in renal carcinoma and NSCLC models. These programs further underscore the company’s versatility in tackling both blood cancers and solid tumors. Anti-Fungal and Anti-Viral Therapies: With preclinical programs targeting fungal infections and other viral diseases, TCBP’s ambitions extend beyond oncology—an intelligent move to broaden its therapeutic pipeline and address critical global health challenges. Recent Developments Driving Progress Partnership with CareDx: In a groundbreaking collaboration, TC BioPharm (NASDAQ: TCBP) has partnered with CareDx, Inc., a leader in precision medicine, to integrate its AlloCell™ solution for pharmacokinetic monitoring in the ACHIEVE clinical trial. This partnership enhances the evaluation of TCB008’s expansion and persistence in AML patients, providing critical insights into its long-term efficacy. According to TCBP’s Executive Vice President of Clinical Operations, Alison Bracchi, "The collaboration is pivotal to the development and optimization of TCB008 as a therapy for acute myeloid leukemia and other blood cancers." ACHIEVE UK Trial Updates: Recent updates on the ACHIEVE UK trial highlight positive safety data that allow for exploring higher doses of TCB008. With four active clinical sites and two more expected in 2025, the trial’s progress is accelerating. Over half the Cohort A patients have already received treatment, showcasing TCB008’s promising safety profile even at increased dosages. Additionally, advancements in manufacturing processes have enabled scaled-up production and cost reductions, ensuring broader access and sustainability. Operational Milestones: In late 2024, TCBP provided shareholder updates on its remarkable progress. These include the opening of new clinical trial sites like Guy’s and St. Thomas Hospital, ongoing compassionate use programs, and the launch of proof-of-concept preclinical studies for new viral treatments. Furthermore, non-binding agreements for acquisitions in CAR-T and NK therapies reflect the company’s strategic growth trajectory.  Strategic Initiatives and Partnerships Innovation doesn’t happen in isolation, and TC BioPharm (NASDAQ: TCBP) understands this better than most. The company’s collaborations with top-tier institutions like Carnegie Mellon University and Queen Mary University of London showcase its commitment to leveraging external expertise to accelerate progress. Artificial Intelligence (AI): In partnership with Carnegie Mellon, TC BioPharm (NASDAQ: TCBP) is integrating AI into its donor screening process. This initiative aims to optimize donor selection, ensuring the best possible outcomes for patients receiving gamma-delta T-cell therapies. Monkeypox Research: Collaborating with experts at the University of Surrey, TCBP is advancing research into using gamma-delta T-cells to treat mucosal infections and viral diseases like monkeypox. Manufacturing Scale-Up: By October 2025, the company aims to scale its manufacturing capabilities, ensuring that its groundbreaking therapies can reach more patients worldwide. A Fiscally Savvy Operator Despite its clinical-stage status, TC BioPharm (NASDAQ: TCBP) fiscal strategies are as aggressive as its scientific pursuits.  The company is also eyeing strategic acquisitions in the cell therapy space, a move that could further expand its pipeline and market dominance.  With favorable market conditions and active negotiations with acquisition targets, TC BioPharm (NASDAQ: TCBP) is positioning itself to unlock new pathways for growth. Competitive Advantage The cell-based immunotherapy landscape is crowded, but TC BioPharm (NASDAQ: TCBP) stands head and shoulders above the competition.  While others are stuck in preclinical or early clinical phases, (TCBP) is blazing a trail with Phase II pivotal trials and a robust safety and efficacy record.  Its vertically integrated approach—from R&D to cGMP manufacturing—ensures speed and scalability, giving it a decisive edge in the race to market. Looking Ahead The next few years promise to be transformative for TCBP: ACHIEVE Phase 2b Data: Interim analyses in mid-2025 will provide critical insights into the efficacy of TCB008 in AML. US Expansion: With the ACHIEVE2 (US) study set to begin patient treatment in 2026, TCBP is making its mark across the Atlantic. New Therapeutic Areas: Proof-of-concept studies for antifungal and antiviral applications are set to yield results by the end of 2025, showcasing the versatility of TCBP’s platform. The Bottom Line TC BioPharm (NASDAQ: TCBP) isn’t just another biotech company. It’s a pioneer, a disruptor, and a force to be reckoned with in the world of cell-based immunotherapy.  With its groundbreaking gamma-delta T-cell platform, strategic partnerships, and unwavering commitment to innovation, TC BioPharm (NASDAQ: TCBP) is positioning itself to reshape the future of cancer treatment.  7 Reasons Why TC BioPharm (NASDAQ: TCBP) is #1 On Our Watchlist This Morning… 1. Low Float Suggests Volatility Potential: With a float of under 585K shares (MarketWatch), limited availability could result in significant price movement as interest builds. 2. Analyst-Endorsed Upside with a $3 Target: A recent $3 target from HC Wainwright & Co. signals strong confidence in TC BioPharm (NASDAQ: TCBP)’s potential, pointing to substantial upside from current trading levels. 3. Oversold RSI Levels Could Signal a Reversal: Current RSI readings (9-Day: 25.80%, 14-Day: 25.85%, 20-Day: 29.04%) indicate oversold conditions, which often precede a rebound. 4. Leading Innovation in Gamma-Delta T-Cell Therapies: TC BioPharm (NASDAQ: TCBP)’s  flagship therapy, TCB008, is advancing through Phase II clinical trials for AML, one of the most challenging cancers to treat. 5. AI-Powered Screening to Optimize Outcomes: Through its partnership with Carnegie Mellon University, TC BioPharm (NASDAQ: TCBP) is leveraging artificial intelligence to enhance donor screening and matching processes — a critical step for scaling allogeneic cell therapies. 6. Progress in the ACHIEVE Clinical Trial: Positive safety results, increased dose exploration, and plans to expand to six clinical trial sites demonstrate TC BioPharm (NASDAQ: TCBP)’s steady momentum in its ACHIEVE study. 7. A Growing Pipeline Beyond Oncology: TC BioPharm (NASDAQ: TCBP) is advancing therapies targeting antifungal infections and other viral diseases, showcasing its ability to address a broad range of urgent medical needs. With a low float, analyst-backed upside, and oversold technical indicators, TC BioPharm (NASDAQ: TCBP) stands out as a company to watch.  Its leadership in gamma-delta T-cell therapies, progress in the ACHIEVE trial, and AI-driven innovation demonstrate a clear path forward, while its growing pipeline beyond oncology highlights its potential to address urgent global health needs. TC BioPharm (NASDAQ: TCBP) is #1 on our watchlist this morning. I’m dead serious. Consider taking a look at (TCBP) before the opening bell rings. (TCBP) just made an approximate 189% early move in the pre-market. Are you watching this? We will have (TCBP) on our screen bright and early this morning—so be sure to keep an eye out for my next update. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and Awareness Consulting Network LLC, TD Media LLC has been hired for a period beginning on 12/17/2024 and ending on 12/18/2024 to publicly disseminate information about (TCBP:US) via digital communications. Under this agreement, we have been paid fifteen thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither TD Media LLC or its member owns shares of (TCBP:US).

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice